Novo Ventures invests millions in Bavarian Nordic rival

London-based biotech company Reviral has raised USD 55 million for the continued development of its phase II candidate against the respiratory disease RSV. Novo Ventures is among the investors.

Photo: Novo Holdings/PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles